Mumbai Metro Line 3's Aqua Line extends its services from Bandra-Kurla Complex to Acharya Atre Chowk in Worli, enhancing connectivity to commercial and religious hubs. The newly operational Phase ...

While CAR T cell therapy—a personalized form of cancer immunotherapy first successfully developed by Carl June, MD, and his team at Penn—has revolutionized treatment for many blood cancers ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma. A next-generation "armored" CAR T cell therapy ...

GameSpot may get a commission from retail offers. Almost 12 years after launching, Splinter Cell: Blacklist now supports Steam achievements. Ubisoft has added the functionality to the stealth game ...

MB-105, a CD5-targeted CAR-T cell therapy, is being evaluated in a phase 2 trial for relapsed or refractory CD5-positive T-cell lymphoma. The trial, led by Dr. Swaminathan P. Iyer, will assess ...

According to a post on X by sneaker-focused account Kicks Finder on Tuesday, the 19-year-old will have a special edition of the Nike G.T. Cut 3 Turbo LE, set to release on Aug. 1 for a projected ...

Orca-T was tied to a 78% rate of survival free of moderate to severe cGVHD at the trial's one-year mark, a statistically significant improvement over the 38% rate seen in patients who received ...

Cemacabtagene ansegedleucel, an allogeneic chimeric antigen receptor (CAR) T-cell therapy, is being investigated in relapsed/refractory large B-cell lymphoma. The investigational allogeneic ...

In cohort 1, enrollment required prior treatment with a CD19-directed CAR T-cell therapy, cohort 2 consisted of patients who received a non-conforming dose of firi-cel that was determined to be safe ...

Chimeric antigen receptor (CAR) T-cell therapy has shown efficacy in blood cancers — with six CAR T-cell products now approved by the US Food and Drug Administration (FDA) to treat six ...

The same clone was detectable at a frequency of 0.01% of sequences on day 28 but was not detectable at any previous time point either before or after infusion (days 3 and 14 after CAR T-cell ...

Candid Therapeutics, a new San Diego biotech bent on becoming a leader in the emerging T-cell engager space, has unwrapped three new research collaborations focusing on autoimmune diseases.